{"PubmedBookArticle": [], "PubmedArticle": [{"MedlineCitation": {"KeywordList": [["Bioequivalence", "Bosentan", "High performance liquid chromatography", "Losartan"]], "OtherAbstract": [], "SpaceFlightMission": [], "InvestigatorList": [], "CitationSubset": [], "OtherID": [], "GeneralNote": [], "PMID": "38618512", "DateRevised": {"Year": "2024", "Month": "04", "Day": "16"}, "Article": {"Language": ["eng"], "ELocationID": ["10.18502/ajmb.v16i2.14861"], "ArticleDate": [], "Journal": {"ISSN": "2008-2835", "JournalIssue": {"Volume": "16", "Issue": "2", "PubDate": {"Year": "2024", "Season": "Apr-Jun"}}, "Title": "Avicenna journal of medical biotechnology", "ISOAbbreviation": "Avicenna J Med Biotechnol"}, "ArticleTitle": "Simple Determination of Bosentan in Plasma Samples by Reversed-Phase High-Performance Liquid Chromatography.", "Pagination": {"StartPage": "104", "EndPage": "110", "MedlinePgn": "104-110"}, "Abstract": {"AbstractText": ["In order to measure the plasma levels of Losartan and Bosentan, a sensitive Reverse Phase-High Performance Liquid Chromatography (RP-HPLC) technique was developed.", "To compare bioavailability, the Area Under the Curve (AUC), peak plasma concentration (Cmax), and time to Cmax (Tmax) were employed. The standard curve (150-2400 <i>ng/ml</i>) was linear (R<sup>2</sup>=0.999), relative errors were between 2.4 to 10.05% and the coefficient of variation (CV%) ranged from 1.52 to 10.88. A single dosage (test and reference) was used for the <i>in vivo</i> investigation, which involved 16 healthy individuals.", "The AUC0-48, AUC0-, Cmax, and Tmax of the test and reference had no statistically significant differences. The C<sub>max</sub> and 95% confidence intervals of the ratio of C<sub>max</sub> of the two formulations were 0.93-0.96 and 97.6-135%, respectively.", "Therefore, it was established that generic Bosentan was equivalent to Bosentan from Actelion and that both medications could be regarded as equally effective in clinical settings. The blood level of Bosentan could be measured using this straightforward procedure in all hospital laboratories."], "CopyrightInformation": "Copyright\u00a9 2024 Avicenna Research Institute."}, "AuthorList": [{"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Biotechnology and Medicinal Plants Research Center, Ilam University of Medical Sciences, Ilam, Iran."}], "LastName": "Abbasi", "ForeName": "Naser", "Initials": "N"}], "PublicationTypeList": ["Journal Article"]}, "MedlineJournalInfo": {"Country": "Iran", "MedlineTA": "Avicenna J Med Biotechnol", "NlmUniqueID": "101511065", "ISSNLinking": "2008-2835"}}, "PubmedData": {"ReferenceList": [{"ReferenceList": [], "Reference": [{"Citation": "Rubin LJ, Badesch DB, Barst RJ, Galie N, Black CM, Keogh A, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002;346(12):896\u2013903.", "ArticleIdList": ["11907289"]}, {"Citation": "Kiowski W, S\u00fctsch G, Hunziker P, M\u00fcller P, Kim J, Oechslin E, et al. Evidence for endothelin-1-mediated vasoconstriction in severe chronic heart failure. Lancet (London, England). 1995;346(8977):732\u20136.", "ArticleIdList": ["7658874"]}, {"Citation": "van Giersbergen PL, Halabi A, Dingemanse J. Single- and multiple-dose pharmacokinetics of Bosentan and its interaction with ketoconazole. Br J Clin Pharmacol 2002; 53(6):589\u201395.", "ArticleIdList": ["PMC1874330", "12047483"]}, {"Citation": "Parekh JM, Shah DK, Sanyal M, Yadav M, Shrivastav PS. Development of an SPE-LC-MS/MS method for simultaneous quantification of Bosentan and its active metabolite hydroxyBosentan in human plasma to support a bioequivalence study. J Pharm Biomed Anal 2012;70: 462\u201370.", "ArticleIdList": ["22789899"]}, {"Citation": "Atila A, Ozturk M, Kadioglu Y, Halici Z, Turkan D, Yayla M, et al. Development and validation of UFLC\u2013MS/MS method for determination of Bosentan in rat plasma. J Pharm Biomed Anal 2014;97:33\u20138.", "ArticleIdList": ["24803031"]}, {"Citation": "Bhavya Sri K, Mounika CH. Development and validation of uv-visible spectrophotometric method for analysis of Bosentan in spiked human plasma. International Journal of Current Pharmaceutical Research 2019;11(4):108\u201310."}, {"Citation": "Yokoyama Y, Tomatsuri M, Hayashi H, Hirai K, Ono Y, Yamada Y, et al. Simultaneous microdetermination of Bosentan, ambrisentan, sildenafil, and tadalafil in plasma using liquid chromatography/tandem mass spectrometry for pediatric patients with pulmonary arterial hypertension. J Pharm Biomed Anal 2014;89:227\u201332.", "ArticleIdList": ["24309556"]}, {"Citation": "Qiu X, Zhao J, Wang Z, Xu Z, Xu RA. Simultaneous determination of Bosentan and glimepiride in human plasma by ultra performance liquid chromatography tandem mass spectrometry and its application to a pharmacokinetic study. J Pharm Biomed Anal 2014;95:207\u201312.", "ArticleIdList": ["24685726"]}, {"Citation": "Li H, Zhang S, Tan B, Qiang Y, Li W, Chen S, et al. Investigation of Losartan Potassium as an eco-friendly corrosion inhibitor for copper in 0.5 M H2SO4. Journal of Molecular Liquids 2020;305(1):112789."}, {"Citation": "Qiang Y, Guo L, Li H, Lan X. Fabrication of environmentally friendly Losartan potassium film for corrosion inhibition of mild steel in HCl medium. Chemical Engineering Journal 2021;406:126863."}, {"Citation": "Zhao Z, Wang Q, Tsai EW, Qin XZ, Ip D. Identification of Losartan degradates in stressed tablets by LC-MS and LC-MS/MS. J Pharm Biomed Anal 1999;20(1\u20132):129\u201336.", "ArticleIdList": ["10704016"]}, {"Citation": "Soldner A, Spahn-Langguth H, Mutschler E. HPLC assays to simultaneously determine the angiotensin-AT1 antagonist Losartan as well as its main and active metabolite EXP 3174 in biological material of humans and rats. J Pharm Biomed Anal 1998;16(5):863\u201373.", "ArticleIdList": ["9535198"]}, {"Citation": "Selvadurai M, Meyyanathan SN. Sensitive and accurate estimation of Losartan potassium formulation by high-performance thin-layer chromatography. Pharm Methods 2011;2(2):95\u20138.", "ArticleIdList": ["PMC3658049", "23781437"]}, {"Citation": "Iwasa T, Takano T, Hara K, Kamei T. Method for the simultaneous determination of Losartan and its major metabolite, EXP-3174, in human plasma by liquid chromatography-electrospray ionization tandem mass spectrometry. J Chromatogr B Biomed Sci Appl 1999;734(2):325\u201330.", "ArticleIdList": ["10595730"]}, {"Citation": "Anandakumar K, Jambulingam M, Rmaesh J, Subarla SJ, Sangeetha P, Raja M. Development and validation of RP-HPLC method for the dissolution study of bosentan in bulk and in pharmaceutical dosage form. Current Journal of Applied Science and Technology 2018;18(2)."}, {"Citation": "Weber C, Schmitt R, Birnboeck H, Hopfgartner G, van Marle SP, Peeters PAM, et al. Pharmacokinetics and pharmacodynamics of the endothelin-receptor antagonist bosentan in healthy human subjects. Clin Pharmacol Ther 1996;60(2):124\u201337.", "ArticleIdList": ["8823230"]}, {"Citation": "Khan MA, Sinha S, Todkar M, Parashar V, Swamy Reddy K. Development and validation of a stability indicating analytical method for the related substances of Bosentan drug substance by HPLC. American Journal of Scientific and Industrial Research 2012;3(2):69\u201380."}, {"Citation": "Seth P. An in-vivo bioequivalence study of a new nifedipine extended release dosage form, \u2018Opticaps\u2019. Drug Development and Industrial Pharmacy 2008;20(9): 1605\u201312."}, {"Citation": "Emami J, Varshosaz J, Falamarzian M, Tahvilian R. High performance liquid chromatographic determination, pharmacokinetic and comparative bioavailability studies of cisapride. J Pharm Biomed Anal 2003;33(3):513\u201320.", "ArticleIdList": ["14550869"]}, {"Citation": "Bhadoriya A, Dasandi B, Parmar D, Shah PA, Shrivastav PS. Quantitation of tadalafil in human plasma using a sensitive and rapid LC-MS/MS method for a bioequivalence study. J Pharm Anal 2018;8(4):271\u20136.", "ArticleIdList": ["PMC6104147", "30140492"]}, {"Citation": "Lausecker B, Hess B, Fischer G, Mueller M, Hopfgartner G. Simultaneous determination of Bosentan and its three major metabolites in various biological matrices and species using narrow bore liquid chromatography with ion spray tandem mass spectrometric detection. J Chromatogr B Biomed Sci Appl 2000;749(1):67\u201383.", "ArticleIdList": ["11129080"]}, {"Citation": "Tanaka S, Uchida S, Hakamata A, Miyakawa S, Odagiri K, Inui N, et al. Simultaneous LC-MS analysis of plasma concentrations of sildenafil, tadalafil, bosentan, ambrisentan, and macitentan in patients with pulmonary arterial hypertension. Die Pharmazie 2020;75(6):236\u20139.", "ArticleIdList": ["32539916"]}, {"Citation": "Markert C, Schweizer Y, Hellwig R, Wirsching T, Riedel KD, Burhenne J, et al. Clarithromycin substantially increases steady-state Bosentan exposure in healthy volunteers. Br J Clin Pharmacol 2014;77(1):141\u20138.", "ArticleIdList": ["PMC3895355", "23738582"]}, {"Citation": "Al-Ghazawi M, Tutunji M, Aburuz S. Simultaneous determination of sildenafil and N-desmethyl sildenafil in human plasma by high-performance liquid chromatography method using electrochemical detection with application to a pharmacokinetic study. J Pharm Biomed Anal 2007;43(2):613\u20138.", "ArticleIdList": ["16920325"]}, {"Citation": "Ma B, Shang X, Zhang Q, Li J, Liu Y, Cao X, et al. Rapid analysis of tadalafil in human blood plasma and seminal plasma by liquid chromatography/tandem mass spectrometry. J Pharm Biomed Anal 2013;77:149\u201357.", "ArticleIdList": ["23416369"]}, {"Citation": "Nirogi R, Kandikere V, Komarneni P, Aleti R, Padala N, Kalaikadhiban I. LC-ESI-MS/MS method for quantification of ambrisentan in plasma and application to rat pharmacokinetic study. Biomed Chromatogr 2012;26(10):1150\u20136.", "ArticleIdList": ["22222607"]}, {"Citation": "Enderle Y, Witt L, Wilkens H, Gr\u00fcnig E, Haefeli WE, Burhenne J. Simultaneous quantification of endothelin receptor antagonists and phosphodiesterase 5 inhibitors currently used in pulmonary arterial hypertension. J Pharm Biomed Anal 2017;143:291\u20138.", "ArticleIdList": ["28628863"]}, {"Citation": "Lavudu P, Rani AP, Chander AP, Bala sekaran C. Determination of bosentan in pharmaceutical dosage forms by high performance liquid chromatography. International Journal of Drug Delivery 2013;5(2):146\u201351."}, {"Citation": "Muralidharan Selvadurai, Kumar JR. Simple estimation of bosentan in tablet formulation by RP-HPLC. American Journal of Analytical Chemistry 2012;3(11): 715\u20138."}, {"Citation": "Ohtaka R, Maeda M, Iwagami T, Ueda T, Kimura Y, Imai K, et al. [Precision of internal standard method in HPLC analysis]. Yakugaku Zasshi 2003;123(5):349\u201355. Japanese.", "ArticleIdList": ["12772591"]}, {"Citation": "Mannam RaYI . Estimation of bosentan monohydrate in male rabbit plasma by using RP-HPLC method. Journal of Applied Pharmaceutical Science 2017."}, {"Citation": "Atila A, Yilmaz B. Determination of bosentan in pharmaceutical preparations by linear sweep, square wave and differential pulse voltammetry methods. Iran J Pharm Res 2015;14(2):443\u201351.", "ArticleIdList": ["PMC4403060", "25901151"]}, {"Citation": "Sajedi-Amin S, Asadpour-Zeynali K, Khoubnasabjafari M, Rashidi F, Jouyban A. Development and validation of ultrasound assisted and dispersive liquid-liquid microextractions combined with HPLC-UV method for determination of bosentan in human plasma and urine. Journal of the Brazilian Chemical Society 2017;28(5):868\u201377."}, {"Citation": "Jatczak M, Sidoryk K, Kossykowska M, \u0141uniewski W, Zagrodzka J, Lipiec-Abramska E. Development and validation of a UHPLC UV method for the in-process control of bosentan monohydrate synthesis. Chromatographia 2016;79(17):1131\u201341.", "ArticleIdList": ["PMC4995228", "27616782"]}, {"Citation": "Dey S. Method development and estimation of Bosentan monohydrate in bulk and pharmaceutical dosage forms using UV-Visible Spectrophotometer. Journal of Pharmacy Research 2011;4(6):1713\u20135."}, {"Citation": "Plana JC, Galderisi M, Barac A, Ewer MS, Ky B, Scherrer-Crosbie M, et al. Expert consensus for multi-modality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr 2014; 27(9):911\u201339.", "ArticleIdList": ["25172399"]}, {"Citation": "Bartlett JW, Frost C. Reliability, repeatability and reproducibility: analysis of measurement errors in continuous variables. Ultrasound Obstet Gynecol 2008;31(4):466\u201375.", "ArticleIdList": ["18306169"]}, {"Citation": "Shammas HJ, Hoffer KJ. Repeatability and reproducibility of biometry and keratometry measurements using a noncontact optical low-coherence reflectometer and keratometer. Am J Ophthalmol 2012;153(1):55\u201361.e2.", "ArticleIdList": ["21907967"]}, {"Citation": "Galderisi M, Henein M, D\u2019Hooge J, Sicari R, Badano L, Zamorano J, et al. Recommendations of the European Association of Echocardiography How to use echo-Doppler in clinical trials: Different modalities for different purposes. Eur J Echocardiogr 2011;12:339\u201353.", "ArticleIdList": ["21555455"]}, {"Citation": "Watson PF, Petrie A. Method agreement analysis: a review of correct methodology. Theriogenology 2010;73(9):1167\u201379.", "ArticleIdList": ["20138353"]}, {"Citation": "Karthikeyan K, Mahat MY, Chandrasekaran S, Gopal K, Franklin PX, Sivakumar BJ, et al. Bioanalytical method development, validation and quantification of dorsomorphin in rat plasma by LC-MS/MS. Biomed Chromatogr 2013;27(8):1018\u201326.", "ArticleIdList": ["23526253"]}]}], "History": [{"Year": "2023", "Month": "8", "Day": "7"}, {"Year": "2023", "Month": "10", "Day": "25"}, {"Year": "2024", "Month": "4", "Day": "15", "Hour": "6", "Minute": "44"}, {"Year": "2024", "Month": "4", "Day": "15", "Hour": "6", "Minute": "43"}, {"Year": "2024", "Month": "4", "Day": "15", "Hour": "4", "Minute": "33"}, {"Year": "2024", "Month": "4", "Day": "1"}], "PublicationStatus": "ppublish", "ArticleIdList": ["38618512", "PMC11007376", "10.18502/ajmb.v16i2.14861", "AJMB-16-104"]}}]}